Research programme: BACE1 protein inhibitors - Pfizer
Alternative Names: WAC-547415; WAY-258131; WY-24454Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Fluorobenzenes; Hydantoins; Imidazoles; Pyridines; Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 26 Aug 2010 Pharmacodynamics data from preclinical trials in Alzheimer's disease presented at the 240th American Chemical Society National Meeting (ACS-2010)
- 15 Oct 2009 Wyeth has been acquired by Pfizer